Credit Suisse Group Reiterates “Outperform” Rating for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Share on StockTwits

Credit Suisse Group reissued their outperform rating on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a report published on Wednesday morning, Briefing.com Automated Import reports.

Several other equities analysts have also commented on the stock. LADENBURG THALM/SH SH reaffirmed a buy rating on shares of Paratek Pharmaceuticals in a research report on Thursday, May 9th. Zacks Investment Research raised shares of DLH from a sell rating to a hold rating in a research report on Tuesday, July 9th. BidaskClub lowered shares of Zai Lab from a hold rating to a sell rating in a research report on Wednesday, May 1st. B. Riley reaffirmed a buy rating on shares of Champion Iron in a research report on Wednesday, April 24th. Finally, ValuEngine raised shares of VESTAS WIND SYS/ADR from a hold rating to a buy rating in a research report on Thursday, May 9th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $7.47.

ACRX stock opened at $2.77 on Wednesday. The firm’s 50-day moving average price is $2.46. AcelRx Pharmaceuticals has a one year low of $1.99 and a one year high of $5.05. The company has a quick ratio of 4.91, a current ratio of 5.03 and a debt-to-equity ratio of 0.79.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.85 million. Analysts predict that AcelRx Pharmaceuticals will post -0.84 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in ACRX. BlackRock Inc. raised its position in shares of AcelRx Pharmaceuticals by 196.6% in the 4th quarter. BlackRock Inc. now owns 2,331,736 shares of the specialty pharmaceutical company’s stock valued at $5,386,000 after purchasing an additional 1,545,702 shares during the last quarter. Two Sigma Investments LP increased its holdings in AcelRx Pharmaceuticals by 820.9% in the 4th quarter. Two Sigma Investments LP now owns 559,408 shares of the specialty pharmaceutical company’s stock worth $1,292,000 after buying an additional 498,664 shares during the period. Barclays PLC acquired a new position in AcelRx Pharmaceuticals in the 4th quarter worth approximately $805,000. Norges Bank acquired a new position in AcelRx Pharmaceuticals in the 4th quarter worth approximately $578,000. Finally, Tibra Equities Europe Ltd acquired a new position in AcelRx Pharmaceuticals in the 1st quarter worth approximately $521,000. 15.53% of the stock is owned by hedge funds and other institutional investors.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Recommended Story: How is a management fee different from a performance fee?

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.